Mutational screening of the USH2A gene in Spanish USH patients reveals 23 novel pathogenic mutations

Gema Garcia-Garcia1, Maria J Aparisi1, Teresa Jaijo1,2, Regina Rodrigo1, Ana M Leon2, Almudena Avila-Fernandez2,3, Fiona Blanco-Kelly3, Sara Bernal2,4, Rafael Navarro5, Manuel Diaz-Llopis6, Montserrat Baiget2,4, Carmen Ayuso2,3, Jose M Millan1,2,7* and Elena Aller1,2

Abstract

Background: Usher Syndrome type II (USH2) is an autosomal recessive disorder, characterized by moderate to severe hearing impairment and retinitis pigmentosa (RP). Among the three genes implicated, mutations in the USH2A gene account for 74-90% of the USH2 cases.

Methods: To identify the genetic cause of the disease and determine the frequency of USH2A mutations in a cohort of 88 unrelated USH Spanish patients, we carried out a mutation screening of the 72 coding exons of this gene by direct sequencing. Moreover, we performed functional minigene studies for those changes that were predicted to affect splicing.

Results: As a result, a total of 144 DNA sequence variants were identified. Based upon previous studies, allele frequencies, segregation analysis, bioinformatics predictions and in vitro experiments, 37 variants (23 of them novel) were classified as pathogenic mutations.

Conclusions: This report provide a wide spectrum of USH2A mutations and clinical features, including atypical Usher syndrome phenotypes resembling Usher syndrome type I. Considering only the patients clearly diagnosed with Usher syndrome type II, and results obtained in this and previous studies, we can state that mutations in USH2A are responsible for 76.1% of USH2 disease in patients of Spanish origin.

Keywords: Usher Syndrome, USH2A, Mutations, Sequence Variants

Disease Name and Definition

Usher syndrome

Usher syndrome (USH) is an autosomal recessive disease characterized by hearing loss, retinitis pigmentosa (RP), and, in some cases, vestibular dysfunction. It is clinically and genetically heterogeneous and is the most common cause underlying deafness and blindness of genetic origin. Clinically, USH is divided into three types. Usher type I (USH1) is the most severe form and is characterized by severe to profound congenital deafness, vestibular areflexia, and prepubertal onset of progressive RP. Type II (USH2) displays moderate to severe hearing loss, absence of vestibular dysfunction, and later onset of retinal degeneration. Type III (USH3) shows progressive postlingual hearing loss, variable onset of RP, and variable vestibular response. To date, five USH1 genes have been identified: MYO7A (USH1B), CDH23 (USH1D), PCDH15 (USH1F), USH1C(USH1C), and USH1G(USH1G). Three genes are involved in USH2, namely, USH2A (USH2A), GPR98 (USH2C), and DFNB31 (USH2D). USH3 is rare except in certain populations, and the gene responsible for this type is USH3A.

Background

Usher syndrome (USH) is an autosomal recessive disease characterized by the association of hearing loss and visual impairment due to retinitis pigmentosa (RP), with or without vestibular dysfunction. It is the most
frequent cause of concurrent deafness and blindness of genetic origin and its general prevalence ranges from 3.3 to 6.4 per 100,000 live births [1]. In Spain, the estimation is 4.2/100,000 [2].

USH is clinically and genetically heterogeneous. Three clinical forms are distinguished: USH1, USH2 and USH3 and nine genes have been identified responsible so far. Five causative genes have been reported for USH1: MYO7A, USH1C, CDH23, PCDH15 and USH1G. Three genes for USH2: USH2A, GPR98 and DFNB31. Meanwhile only one gene has been described for USH3: USH3A [3,4].

USH2 appears to be the most common clinical form of the disorder, accounting for more than 50% of all Usher cases [5,6]. Among the three genes described for USH2, USH2A is the most commonly mutated gene. It is responsible for approximately 74-90% of USH2 cases [2,7]. Mutations in USH2A, are also responsible for atypical Usher syndrome and recessive non-syndromic RP [8,9]. The USH2A gene, located on chromosome 1q41 [10], was initially described as comprising 21 exons, encoding a protein of 1546 amino acids [11,12]. However, in 2004, van Wijk et al. (2004) identified 51 additional exons at the 3’ end of USH2A [13]. The longest transcript consists of 72 exons, encoding a protein of 5202 amino acids. In addition, Adato et al. (2005), identified an alternative spliced exon 71 in mouse transcripts, expressed in the inner ear and well conserved in vertebrates [14]. The long isoform b is characterized by containing a transmembrane region, followed by an intracellular domain with a PDZ-binding motif, which interacts with the PDZ domain of harmonin and whirlin, integrating USH2A into the USH protein network [14,15].

Initially, studies of the USH2A gene covered just exons 2-21 [11,16-18,8,12,19,20,9,21,22], but only 45-63% of the expected USH2A mutations were identified. Nevertheless, since the discovery of the long isoform, several mutational analyses of all 72 exons have been carried out in diverse populations [23-30]. As a result, many novel pathogenic mutations have been identified, including splicing mutations at non-canonical positions of splice sites [31]. However, the majority of these changes only appear in a few cases, with the exception of the common ancestral p.Glu767fs mutation, located at exon 13, which is the most prevalent USH2A mutation in several populations [16].

In the present study we have performed an exhaustive mutational screening of the long isoform b of USH2A to identify new patients with mutations in this gene, and to detect the second mutation in patients with one previously detected USH2A mutation. Some cases had previously been studied for exon 13 or for the 21 first USH2A exons [19,9], or analyzed using the genotyping microarray for Usher syndrome (Asper Biotech, Tartu, Estonia; [32]). Furthermore, we have used in silico and in vitro analysis to evaluate the functional consequences on gene expression and protein function of several nucleotide changes.

Materials and methods

Subjects

Eighty-eight (88) unrelated Spanish patients diagnosed of Usher syndrome were included in this study. They were recruited from the Federación de Afectedos de Retinosis Pigmentaria de España (FARPE) and also from the Ophthalmology and ENT Services of several Spanish Hospitals as part of a large-scale study on the genetics of Usher syndrome in the Spanish population.

On the basis of their clinical history and ophthalmologic, audiological, neurophysiological and vestibular tests, 58 of these families were clinically classified as USH2 while 11 displayed atypical Usher syndrome. Detailed clinical data could not be obtained for 19 patients and these remained as non classified (USHNC).

Previously, 40 of these 88 patients were studied for exon 13, while 24 were analysed for the first 21 exons of USH2A and 42 were analyzed with the genotyping microarray for Usher syndrome (Asper Biotech, Tartu, Estonia). At that time, the version of the array detected 429 previously described mutations in eight of the nine genes reported for the disease. As a result of these previous analyses, eighteen of them were found to carry one mutated allele, but the second mutation could not be detected. These mutations have been included in the statistical summaries presented herein. These patients were subjected to mutation screening of the exons that had not been analyzed. In the remaining patients, we carried out the study of exons 2-72 (including the alternatively spliced exon 71).

When DNA samples from patients’ relatives were available, we carried out a segregation analysis. One hundred unrelated individuals of Spanish origin without hearing loss or RP family history were screened as controls to evaluate the frequency of the mutations found in the patient sample.

Mutation analysis

Genomic DNA from patients and controls was extracted from peripheral blood samples following standard protocols. The coding exons and flanking intronic sequences of USH2A were amplified by PCR using primers and conditions described by Aller et al. (2004; 2006) [9,23]. The amplified DNA fragments were analysed by direct sequencing using the Big Dye Terminator v.3.1 kit (Applied Byosistems, Carlsbad, CA), and purified sequencing reactions were analysed in an ABI PRISM 3730 DNA analyzer (Applied Byosistems, Carlsbad, CA).
The obtained sequences were compared with the consensus sequence NM_206933.2. The +1 position corresponds to A in the ATG translation initiation codon.

**Predictions of the pathogenic effect of missense variations**

To predict whether a rare missense variant is deleterious, we used the combined results of three different computer algorithms:

- Sort Intolerant From Tolerant (SIFT) (available at http://sift.jcvi.org) uses sequence homology to predict whether a change is tolerated or deleterious.
- The polymorphism phenotyping program, PolyPhen (available at http://genetics.bwh.harvard.edu/pph/) uses sequence conservation, structure and SWISS-PROT annotation to characterize an amino acid substitution as benign, possibly deleterious or probably deleterious.
- PMut (available at http://mmb2.pcb.ub.es:8080/PMut/) provides prediction by neural networks, which use internal databases, secondary structure prediction and sequence conservation. This program provides a binary prediction of "neutral" or "pathologic".

**Splice-site Prediction programs**

Intronic, isocoding and missense changes were analyzed using the programs NNSPLICE (http://fruitfly.org:9005/seq_tools/splice.html), Human Splicing Finder (HSF) version 2.4 (http://www.umd.be/HSF/) and NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) in order to predict whether those changes could be affecting, creating or eliminating donor/acceptor splice sites.

**Minigene constructions and expression**

Minigene constructs were generated, using the exon trapping expression vector pSPL3. For each mutation, the exon and intronic flanking sequences were amplified using the High Fidelity Phusion polymerase (Finnzymes, Espoo, Finland). Amplicons were inserted between the XhoI/Nhel and XhoI/BamHI restriction sites for the variants p.E2496E and p.V382M, respectively, using T4 DNA ligase (Invitrogen Corporation, Carlsbad, CA). The p.V382M mutation was generated by site-directed mutagenesis. All vectors were confirmed by direct sequencing. The minigene constructs were transfected into COS-7 cells as described before [33]. RNA extraction and RT-PCR analysis was performed as previously described [34,31]. Missplicing percentages were measured using the Alpha Imager 2200 (version 3.1.2) software (AlphaInnotech Corporation, San Francisco, CA, USA).

**Results**

The molecular analysis of the USH2A gene in 88 unrelated USH Spanish patients revealed 37 different pathogenic mutations. Among these, a total of 23 mutations were novel (See Tables 1, 2 and 3). At least one pathogenic mutation was found in 43 out of 88 unrelated patients (48.9%). Thirty-three patients were classified as USH2, five as USHA (atypical Usher syndrome) and five as USHNC (Usher syndrome non classified). In 25 out of these 43 cases the two causative mutations were detected (58.1%), five patients were homozygous and 20 compound heterozygous. Detailed clinical manifestations of these 25 patients and 3 additional patients with one pathogenic and one probably pathogenic mutation (UV3; likely to be pathogenic but cannot formally be proven) are summarized in Table 4.

In this study, a total of 144 variants were detected: 25 were truncating mutations and five were splice-site mutations (located at the conserved AG/GT dinucleotides of the splice site). The pathogenic effect of these variants is clear. But, in addition, 48 missense, 20 silent and 46 intronic variants were identified. According to previous studies, allele frequencies, segregation analysis, bioinformatics' predictions and in vitro experiments, the missense, silent and intronic changes were classified into 4 different categories: pathogenic, possibly pathogenic (UV3), possibly non-pathogenic (possibly neutral, UV2) and non-pathogenic (neutral). (See Tables 1, 2, 3 and 5).

**Missense variants**

Fourty-eight missense variants were identified (See Table 2). Twenty-nine were considered as non-pathogenic because all of them were already described as non-pathogenic in other studies [https://grenada.lumc.nl/LOVD2/Usher_montpellier, [35]]. Nine nucleotide changes were classified as possibly non-pathologic (UV2). p.G713R, p.S841Y, p.S2196T, p.S2639P, p.G4692R and p.K5026E have already been reported in other works and categorized as possibly non-deleterious or of unknown pathogenicity [https://grenada.lumc.nl/LOVD2/Usher_montpellier, [35]]. Meanwhile, p.N2377S, p.N2394K and p.E4921K have not been described previously, so they were analyzed with the three sequence analysis programs (SIFT, Polyphen and PMUT). None of those changes was predicted to be clearly deleterious (See Table 6).

Four missense variants were classified as possibly pathogenic (UV3). The variants p.R303H and p.Y1992C were described previously [https://grenada.lumc.nl/LOVD2/Usher_montpellier, [35]]. The novel change p.N3894D was not found in 200 control alleles and the segregation analysis proved that it co-segregates with the disease. However, only one program considered it as clearly pathogenic (See Table 6). The new p.V382M change, which affects the first base of exon 7, was not found in control samples and it was predicted to slightly affect splicing. The minigene assays only revealed a mild
increase of the transcript excluding exon 7 (Figure 1, band d) when the variant was present, in comparison to the wild-type sequence.

Finally, six missense mutations were considered as pathogenic. p.C759F and p.C3267R were already described by others authors as damaging [https://grenada.lumc.nl/LOVD2/Usher_montpellier, [35]]. p.C3358Y and p.P4818L were classified by McGee et al. (2010) [30] and the LOVD-USH Database as likely-pathogenic (UV3). However, in the present study, p.C3358Y was detected in a patient together with another nucleotide change (p.C3267R) and the segregation analysis confirmed that the mutations were not in the same allele. p.P4818L was detected in a patient together with two other mutations that directly or indirectly cause a truncated protein (p.Q3368X and c.5278delG). The segregation analysis confirmed that the deletion and the nonsense mutation were in cis and the missense variant was in the other allele and cosegregated with the disease. The segregation analyses support the damaging effect of p.C3358Y and p.P4818L, so we have considered them as pathogenic.

Table 1 USH2A truncating and splice-site mutations

| Nucleotide change | Exon | Predicted effect | Predicted pathology | No. of alleles | References |
|-------------------|------|------------------|---------------------|---------------|------------|
| Nonsense mutations |
| c.820C > T        | 5    | p.R274X          | +                   | 2             | Present study |
| c.1518T > A       | 8    | p.Y506X          | +                   | 1             | Bernal et al., 2005 |
| c.383C > T        | 18   | p.R1295X         | +                   | 1             | Dreyer et al., 2000 |
| c.4474G > T       | 21   | p.E1492X         | +                   | 2             | Bernal et al., 2005 |
| c.4645C > T       | 22   | p.R1549X         | +                   | 1             | Baux et al., 2007 |
| c.7854G > C       | 41   | p.W2618X         | +                   | 1             | Present study |
| c.9753T > A       | 50   | p.C3251X         | +                   | 2             | Present study |
| c.10102C > T      | 51   | p.Q3368X         | +                   | 1             | Present study |
| c.10759C > T      | 55   | p.Q3358T         | +                   | 2             | Baux et al., 2007 |
| c.11146C > T      | 57   | p.Q3716X         | +                   | 1             | Present study |
| c.14175G > A      | 65   | P.W4725X         | +                   | 1             | Present study |
| Deletions and insertions |
| c.918_919insGCTG  | 6    | p.S307AfsX17     | +                   | 1             | Present study |
| c.1214delA        | 7    | p.N405IfsX3      | +                   | 5             | Bernal et al., 2005 |
| c.1629_1645del    | 10   | p.F543LfsX2      | +                   | 1             | Present study |
| c.2299delG        | 13   | p.E7675fsX21     | +                   | 8             | Eudy et al., 1998 |
| c.5278delG        | 26   | p.D1760MfsX10    | +                   | 1             | Present study |
| c.5540_5541dup    | 27   | p.N1848X         | +                   | 1             | Present study |
| c.6319_6324delinsTAAA | 32   | p.V2107X         | +                   | 1             | Present study |
| c.8890dupT        | 45   | p.W2964LfsX89    | +                   | 1             | Present study |
| c.8954delG        | 45   | p.G2985AfsX3     | +                   | 1             | Present study |
| c.9261delT        | 47   | p.E3088KfsX9     | +                   | 1             | Present study |
| c.10272_10273dupTT| 52   | p.C3425FfsX4     | +                   | 1             | Aller et al., 2006 |
| c.11566delA       | 60   | p.S3856VfsX28    | +                   | 1             | Present study |
| c.12093delC       | 62   | p.Y4031X         | +                   | 1             | Present study |
| c.13140delA       | 63   | p.V4381CfsX10    | +                   | 1             | Present study |
| Splice-site mutations |
| c.1328 + 1G > T   | IVS7  | Ex7 splice defect | +                   | 1             | Present study |
| c.1841-2A > G     | IVS10  | Ex11 splice defect | +                   | 2             | Bernal et al., 2003 |
| c.11548 + 2T > G  | IVS59  | Ex59 splice defect | +                   | 1             | Present study |
| c.12067-2A > G    | IVS61  | Ex62 splice defect | +                   | 4             | Auslender et al., 2008 |
| c.15053-1G > A    | IVS69  | Ex70 splice defect | +                   | 1             | Present study |

+: Denotes pathogenic mutations.
No. of alleles: Number of alleles identified in patients.
*These two mutations are allelic.
Novel pathogenic mutations described in this study are in bold.
| Nucleotide change | Exon | Amino acid change | Predicted pathology | No. of alleles | Ref.                  |
|-------------------|------|-------------------|---------------------|----------------|----------------------|
| c.373G > A        | 2    | p.A125T           |                     | 81             | Dreyer et al., 2000 |
| c.130G > A        | 2    | p.G44R            | +                   | 1              | Present Study        |
| c.688G > A        | 4    | p.V230M           |                     | 3              | Dreyer et al., 2000 |
| c.908G > A        | 6    | p.R303H<sup>c</sup> | UV3                | 1              | Yan et al., 2009    |
| c.1144G > A       | 7    | p.V382M<sup>b</sup> | UV3                | 1              | Present Study        |
| c.1434G > C       | 8    | p.E478D           |                     | 4              | Seyedahmadi et al., 2004 |
| c.1663C > G       | 10   | p.L555V           |                     | 2              | Bernal et al., 2003 |
| c.1931A > T       | 11   | p.D644V           |                     | 6              | Weston et al., 2000 |
| c.2137G > C       | 12   | p.G713R           | UV2                 | 2              | Dreyer et al., 2000 |
| c.2276G > T       | 13   | p.C759F           | +                   | 3              | Dreyer et al., 2000 |
| c.2522C > A       | 13   | p.S841Y           | UV2                 | 1              | Jaijo et al., 2009  |
| c.4457G > A       | 21   | p.R1486K          |                     | 75             | Dreyer et al., 2000 |
| c.4714C > T       | 22   | p.L1572F          |                     | 7              | Dreyer et al., 2008 |
| c.4994T > C       | 25   | p.I1665T          |                     | 31             | Kaiserman et al., 2007 |
| c.5975A > G       | 30   | p.Y1992C<sup>c</sup> | UV3                | 1              | McGee et al., 2010  |
| c.6317T > C       | 32   | p.I2106T          |                     | 117            | Aller et al., 2006  |
| c.6506T > C       | 34   | p.I2169T          |                     | 85             | Aller et al., 2006  |
| c.6587G > C       | 34   | p.S2196T          | UV2                 | 2              | Jaijo et al., 2009  |
| c.6713A > C       | 35   | p.E2238A          |                     | 1              | Aller et al., 2006  |
| c.6875G > A       | 36   | p.R2292H          |                     | 2              | Dreyer et al., 2008 |
| c.7130A > G       | 38   | p.N2377S          | UV2                 | 1              | Present Study        |
| c.7182C > A       | 38   | p.N2394K          | UV2                 | 1              | Present Study        |
| c.7506G > A       | 40   | p.P2502P          |                     | 11             | Baux et al., 2008   |
| c.7685T > C       | 41   | p.V2562A          |                     | 1              | Dreyer et al., 2008 |
| c.7915T > C       | 41   | p.S2639P          | UV2                 | 3              | McGee et al., 2010  |
| c.8624G > A       | 43   | p.R2875Q          |                     | 9              | Aller et al., 2006  |
| c.8656C > T       | 43   | p.L2886F          |                     | 9              | Aller et al., 2006  |
| c.9262G > A       | 47   | p.E3088K          |                     | 1              | Dreyer et al., 2008 |
| c.9296A > G       | 47   | p.N3099S          |                     | 12             | Aller et al., 2006  |
| c.9343A > G       | 47   | p.T3115A          |                     | 9              | Dreyer et al., 2008 |
| c.9430G > A       | 48   | p.D3144N          |                     | 8              | Aller et al., 2006  |
| c.9559A > G       | 49   | p.N3199D          |                     | 9              | Baux et al., 2007   |
| c.9799T > C       | 50   | p.C3267R          | +                   | 5              | Aller et al., 2006  |
| c.10073G > A      | 51   | p.C3358Y          | +                   | 1              | McGee et al., 2010  |
| c.10232A > C      | 52   | p.E3411A          |                     | 94             | Aller et al., 2006  |
| c.10636G > A      | 54   | p.G3546R          | +                   | 4              | Present Study        |
| c.1104C > T       | 59   | p.T3835I          |                     | 30             | Present Study        |
| c.11602A > G      | 60   | p.M3868V          |                     | 34             | Aller et al., 2006  |
| c.11677C > A      | 60   | p.P3893T          |                     | 2              | Dreyer et al., 2008 |
| c.11680A > G      | 60   | p.N3894D          | UV3                 | 1              | Present Study        |
| c.12343C > T      | 63   | p.R4115C          |                     | 2              | van Wijk et al., 2004 |
| c.14074G > A      | 64   | p.G6692R<sup>c</sup> | UV2                | 1              | McGee et al., 2010  |
| c.14453C > T      | 66   | p.P4818L          | +                   | 1              | Aller et al., 2006  |
| c.14513G > A      | 66   | p.G4838E          |                     | 1              | McGee et al., 2010  |
| c.14545G > A      | 66   | p.R4848Q          | -                   | 1              | McGee et al., 2010  |
| c.14761G > A      | 67   | p.E4921K          | UV2                 | 1              | Present Study        |
| c.15076A > G      | 70   | p.K5026G          | UV2                 | 1              | McGee et al., 2010  |
G44R and p.G3546R were novel; none of them was detected in 200 control alleles. The variant p.G44R was detected in a single patient and p.G3546R in three cases (one homozygous and two compound heterozygous cases); the results of the three computational analyses classified them as pathogenic (See Table 6).

Silent variants
We also identified 20 silent variants, 17 were previously described as neutral [[36], https://grenada.lumc.nl/LOVD2/Usher_montpellier, [35]] and three were novel (See Table 3). Only the variant p.E2496E was categorized as pathogenic. It was not found in 200 control alleles and the segregation analysis confirmed that this mutation co-segregates with the disease. We detected this variant in trans in a patient who also had a premature stop codon. According to in silico analyses, it was predicted to create a de novo donor splice site (data not shown). The splicing alteration was confirmed using hybrid minigenes. The mutant construct generated a transcript that lacked the last 106 nucleotides of exon 40 (Figure 1, band b). This loss of nucleotides creates a new open reading frame, leading to a premature stop codon five amino acids downstream.

Intronic variants
Forty-six intronic variants located at non-canonical positions of splice sites, of which 20 are novel, were detected in 200 control alleles and the segregation analysis confirmed that this mutation co-segregates with the disease. We detected this variant in trans in a patient who also had a premature stop codon. According to in silico analyses, it was predicted to create a de novo donor splice site (data not shown). The splicing alteration was confirmed using hybrid minigenes. The mutant construct generated a transcript that lacked the last 106 nucleotides of exon 40 (Figure 1, band b). This loss of nucleotides creates a new open reading frame, leading to a premature stop codon five amino acids downstream.

| Nucleotide change | Amino acid position | Predicted pathology | No. of alleles | Ref. |
|-------------------|---------------------|---------------------|----------------|-----|
| c.504A > G        | 3                   | p.T168T             | -              | 75  | Baux et al., 2008 |
| c.1179A > G       | 7                   | p.Q393Q             | -              | 1   | Aller, 2008       |
| c.1419C > T       | 8                   | p.T473T             | -              | 36  | Dreyer et al., 2000 |
| c.2109T > C       | 12                  | p.D703D             | -              | 7   | Weston et al., 2000 |
| c.2256T > C       | 13                  | p.H752H             | -              | 3   | Dreyer et al., 2008 |
| c.3945T > C       | 18                  | p.N1315N            | UV2            | 3   | Present Study     |
| c.2057G > A       | 20                  | p.S1457S            | -              | 1   | Dreyer et al., 2000 |
| c.3571C > T       | 28                  | p.Y1917Y            | UV2            | 1   | Aller et al., 2006 |
| c.7488A > G       | 40                  | p.E2496E<sup>b</sup> | +              | 1   | Present Study     |
| c.7506G > A       | 40                  | p.P2502P            | -              | 11  | McGee et al., 2010 |
| c.11176G > A      | 61                  | p.E3912E            | -              | 2   | Dreyer et al., 2008 |
| c.11190C > T      | 61                  | p.P3969P            | -              | 2   | Dreyer et al., 2008 |
| c.11946A > T      | 61                  | p.L3982L            | -              | 29  | Dreyer et al., 2008 |
| c.12093C > T      | 62                  | p.Y4031Y            | -              | 1   | Dreyer et al., 2008 |
| c.12612A > G      | 63                  | p.T4204T            | -              | 129 | Dreyer et al., 2008 |
| c.12666A > G      | 63                  | p.T4222T            | -              | 58  | Dreyer et al., 2008 |
| c.13191G > A      | 63                  | p.E4397E            | -              | 23  | Dreyer et al., 2008 |
| c.14481C > T      | 66                  | p.A4827A            | -              | 1   | McGee et al., 2010 |
| c.14664G > A      | 67                  | p.T4888T            | UV2            | 1   | Present Study     |

<sup>a</sup>: Denotes pathogenic mutations; UV2: probably non-pathogenic mutations; - : neutral variants.
No. of alleles: Number of alleles identified in patients.
<sup>b</sup>These variant may alter normal splicing.
<sup>c</sup>These variant may alter normal splicing.
<sup>d</sup>These variant may alter normal splicing.
<sup>e</sup>These variant may alter normal splicing.
<sup>f</sup>These variant may alter normal splicing.
<sup>g</sup>These variant may alter normal splicing.
<sup>h</sup>These variant may alter normal splicing.
<sup>i</sup>These variant may alter normal splicing.
<sup>j</sup>These variant may alter normal splicing.
<sup>k</sup>These variant may alter normal splicing.
<sup>l</sup>These variant may alter normal splicing.
<sup>m</sup>These variant may alter normal splicing.
<sup>n</sup>These variant may alter normal splicing.
<sup>o</sup>These variant may alter normal splicing.
<sup>p</sup>These variant may alter normal splicing.
<sup>q</sup>These variant may alter normal splicing.
<sup>r</sup>These variant may alter normal splicing.
<sup>s</sup>These variant may alter normal splicing.
<sup>t</sup>These variant may alter normal splicing.
<sup>u</sup>These variant may alter normal splicing.
<sup>v</sup>These variant may alter normal splicing.
<sup>w</sup>These variant may alter normal splicing.
<sup>x</sup>These variant may alter normal splicing.
<sup>y</sup>These variant may alter normal splicing.
<sup>z</sup>These variant may alter normal splicing.
| Patient   | Mutations                        | Year of Birth | Diagnosis          | Age of diagnosis | Sensoneural Hearing Loss | Vestibular Function | Onset of Night Blindness | Onset of Visual Field Loss | Visual Field | Visual Acuity | Eye Fundus | ERG | Cataracts |
|-----------|---------------------------------|---------------|--------------------|------------------|--------------------------|---------------------|--------------------------|-----------------------------|---------------|---------------|-----------|-----|-----------|
| RP1310*  | c.12067-2A > G/ c.12067-2A > G  | USHNC         | UHD                |                  | Normal                   |                     |                          |                             |               |               |           |     |           |
| RP1274*  | p.E1492X/p.E1492X               | 1969          | UHD                | 25               | Moderate-severe and stable | Normal             | 25                       | 25                          | Concentric loss   | 0,2/0,4       | 1         | No response | BE |
| RP1633   | p.E1492X/p.E1492X               | 1962          | UHD                | 25               | Since infancy            | Normal             | 16                       | 25                          | Marked concentric loss | 0,6/0,6       | 1         | Moderate alteration | BE |
| RP1607   | p.G3546R/p.G3546R               | 1925          | UHD                | 33               | Mild-moderate            | Normal             | 20                       | 30                          | Moderate concentric loss | 0,6/0,7       | 1         | Moderate alteration | BE |
| RP1599*  | c.1214delA/c.1214delA           | 1980          | UHD                | 20               | Moderate, since infancy  | Normal             | 20                       | 30                          | Moderate concentric loss | 0,6/0,7       | 1         | Moderate alteration | BE |
| RP259    | c.1214delA/p.C3267R             | 1974          | USHA               | 19               | Profound since 6 years   | Vestibular Dysfunction | 6                        | Concentric loss (19 years) | 0,35/0,35 (19 years) | 1             | No response | No (19 years) |
| RP1349   | c.2299delG/c.1214delA           | 1954          | UHD                | 15               | Moderate-severe          | Normal             | 15                       | 20                          | Marked concentric loss | 0,4/0,3 (30 years) | 2         |           |       |
| RP1493   | c.2299delG/c.8890dupT           | 1973          | UHD                | 30               | Congenital, moderate and stable | Normal | 29                       | 29                          | Concentric loss (at 31 years) | Normal (31 years) | 1         | No response | No (31 years) |
| RP1632   | c.2299delG/c.8954delG           | 1961          | UHD                | 23               | Since infancy            | Normal             | 23                       | 25                          |                     | <0,1BE        | 2         | No response | BE |
| RP1715*  | c.2299delG/ c.1629_1645del    | 1986          | UHD                | 16               | Moderate and stable      | Normal             | 16                       | 20                          | Slight concentric loss (at 25 years) | Normal (25 years) | 1         | No response | No |
| RP1775   | c.2299delG/p.R303H              | 1961          | USHA               | 30               | Moderate since 7 years and progressive |                 | 23                       | 22                          |                             |               |           |           |     |           |
| RP1618   | p.C3267R/c.6319_6324delinsTAAA | 1964          | UHD                | 30               | Severe-profound          | Normal             | 30                       | 30                          | Marked concentric loss   | 0,1/0,1       | 2         | No response | BE |
| RP1442*  | p.C3267R/c.12093delC            | 1962          | UHD                | 15               | Congenital, moderate and stable | Normal | 15                       | 20                          | Concentric loss, 5° (at 43 years) | 0,5/0,2 (43 years) | 2         | LE (37 years) RE (43 years) |
| RP1703*  | p.C3267R/p.C3358Y              | 1936          | USHA               | 50               | Since 64 years           |                   | 50                       | 55                          | Reduced (67 years) | 1             | Yes        |           |     |           |
| RP1759   | p.C3267R/p.Y1992C              | 1945          | UHD                | 62               | Congenital, moderate and stable | Normal | 62                       | 62                          |                             | Abnormal response | Yes (62 years) |
| RP1625*  | c.12067-2A > G/p.R274X         | 1976          | UHD                | 19               | Since infancy            | Normal             | 19                       | 24                          | Concentric loss   | 0,1/0,1       | 2         | No response | BE |
| RP1631   | c.1841-2A > G/p.R274X         | 1976          | UHD                | 28               | Since infancy            | Normal             | 28                       | 28                          | Concentric loss   | 0,7/0,6       | 1         | No         |     |           |

Garcia-Garcia et al. Orphanet Journal of Rare Diseases 2011, 6:65
http://www.ojrd.com/content/6/1/65
Table 4 Genotype-phenotype correlations of USH patients with both mutations found in this study (Continued)

| Genotype-phenotype | RP951 | c.1214delA/p.C3251X | 1969 | USH2 | 25 | Congenital, severe and stable | Normal✓ | 25 | 18 | Reduced (23 years) | 2 | No response (30 years) | No (30 years) |
|---------------------|-------|----------------------|------|------|----|----------------------------|---------|----|----|-----------------|----|------------------|------------|
| RP1558              | p.R1549X/c.1328 + 1G > T | 1933 | USH2 | 43 | Severe and progressive since 20 years | Normal✓ | Before puberty | -10°C | 0.007/0.03 | 2 |
| RP1539*             | p.R1295X/p.N3894D* | 1987 | USH2 | 20 | Congenital, moderate and stable | Normal✓ | 20 | 17 | Concentric loss (20 years) | 2 |
| RP1172*             | c.10272_10273dupTT/p. W2618X | 1964 | USH2 | 23 | Moderate and stable since 7 years | Normal✓ | 23 | 18 | Concentric loss (38 years) | No response (39 years) |
| RP1641*             | p.C759F/p.W4725X | 1967 | USHA | Moderate and progressive | Central vestibular pathology✓ | 18 | 22 | Marked concentric loss | 0,1/0,2 | 2 | No response | BE |
| RP1667*             | p.C759F/c.11548 + 2T > G | 1954 | USH2 | 15 | Mild and slightly progressive | Normal✓ | 15 | 8 | No response (30 years) | RE (30 years) |
| RP946*              | p.Q3587X/p.E2496E | 1982 | USHNC | 17 | Profound | Normal✓ | 15 | 20 | Marked concentric loss | 0,1/0,1 | 2 | No response | BE |
| RP1613              | c.9260delT/p.G44R | 1971 | USH2 | 30 | Severe | Normal✓ | 20 | 20 | Marked concentric loss | 0,1/0,6 | 2 | Abnormal response | BE |
| RP1615              | c.11566delA/c.15053-1G > A | 1975 | USH2 | 27 | Moderate since infancy | Normal✓ | 24 | 25 | Marked concentric loss | 0,5/0,5 | 2 | No response | BE |

*Parental origin of the mutations was determined; #Patients with possibly pathogenic mutations (UV3).
Age of diagnosis, onset of night blindness and visual field loss are expressed in years.
A: results of clinical examinations; B: self reported symptoms.
Eye fundus 1: Bone spicules deposits, attenuation of vessels and waxy poll of the optic nerve head. Eye fundus 2: 1 + macular affectation.
ERG: Electroretinography; BE: Both Eyes; LE: Left Eye; RE: Right Eye.
Patients clinically classified as USHA or USHNC are highlighted in bold.
in the USH2A gene sequence. According to computational analysis, most of these novel variants were classified as possibly non-pathologic (UV2). (See Table 4).

**Discussion**

In the present study, we have performed a wide mutational screening of the USH2A gene in 88 unrelated Spanish patients diagnosed with Usher syndrome. This analysis has led us to identify a total of 37 different pathogenic mutations, 23 of which had not been previously described: six nonsense, eleven deletions/insertions, two missense, three splice-site mutations and one isocoding variant. At least one mutation was identified in 43 cases and the two responsible mutations were detected in 25 patients (five homozygous and 20 compound heterozygous cases).

The genotype-phenotype correlation for those patients bearing two mutations is illustrated in Table 5. Most cases presented with classical USH2 clinical features. But, interestingly, in one patient (RP-259), the sensorineural hearing loss was profound, RP started at the age of 6 years and he also had vestibular dysfunction (clinical findings typical for USH1). In another intriguing case, phenotype manifestations started at the age of 50 years (RP-1703). We cannot discard the possibility that additional changes in USH2A or in other USH genes, present in these patients, have some modifying effect on the phenotype [37,38].

It is complicated to predict the consequences of missense, silent and intronic changes, in order to discriminate neutral variants from those with a pathogenic effect. We have used a number of bioinformatics' tools to predict the damaging effect of these variants. However, we must bear in mind that these results are only computing predictions and additional studies are necessary to confirm the effect of those changes not clearly classified. In this sense, in vitro analyses for two variants located at non canonical splice sites which were predicted to affect the splicing (p.E2496E and p.V382M) showed that p.E2496E creates a de novo donor splice site stronger than the wild type site that leads to the loss of the last 106 nucleotides of exon 40. Thus, we have considered it as pathogenic. On the other hand, the presence of p.V382M revealed a mild increase of the transcript excluding exon 7 (Figure 1, band d) when the variant was present, but still, the normal transcript has a

### Table 5 Novel intronic variants

| Nucleotide change | Intron | Predicted pathology | No. of alleles |
|-------------------|--------|---------------------|---------------|
| c.1328 + 52T > C  | IVS7   | -                   | 3             |
| c.1841-61G > A    | IVS10  | -                   | 11            |
| c.4627 + 32G > T  | IVS21  | UV2                 | 1             |
| c.6485 + 18C > T  | IVS33  | UV2                 | 1             |
| c.6486-54T > C    | IVS33  | UV2                 | 2             |
| c.6486-43T > A    | IVS33  | UV2                 | 1             |
| c.6657 + 29C > A  | IVS34  | UV2                 | 1             |
| c.8681 + 18A > G  | IVS43  | UV2                 | 1             |
| c.8681 + 53T > G  | IVS43  | UV2                 | 1             |
| c.8681 + 118A > G | IVS43  | UV2                 | 1             |
| c.9056-52G > T    | IVS45  | UV                  | 1             |
| c.9372-50A > G    | IVS47  | UV2                 | 2             |
| c.9740-59G > A    | IVS49  | UV2                 | 1             |
| c.9958 + 128A > G | IVS50  | -                   | 4             |
| c.10388-123T > C  | IVS52  | UV2                 | 1             |
| c.13812-78A > G   | IVS63  | UV2                 | 1             |
| c.14134-53T > C   | IVS64  | UV2                 | 2             |
| c.14343 + 36G > C | IVS65  | UV2                 | 1             |
| c.15298-35T > A   | IVS70  | UV2                 | 1             |
| c.15298-1153G > A  | IVS71  | UV2                 | 1             |

UV2: probably non-pathogenic mutations; - : neutral variants. No. of alleles: Number of alleles identified in patients.

*The intronic variant g.798209G > A affects the last nucleotide of the cochlea specific exon 71. g.DNA numbering starts at nucleotide position 1 in Human RefSeq: NG_009497.1 GI:222352133, which represents the minus (-) strand of USH2A.*

in the USH2A gene sequence. According to computational analysis, most of these novel variants were classified as possibly non-pathologic (UV2). (See Table 4).

### Table 6 Results from the three different analysis programs used to predict the pathogenicity of novel missense changes

| Amino acid change | SIFT | PolyPhen | PMUT |
|-------------------|------|----------|------|
| p.G44R            | Affect (Score 0.01) | Probably damaging | Pathogenic (NN output 0.5113) |
| p.N2377S          | Tolerated (Score 0.44) | Possibly damaging | Neutral (NN output 0.2372) |
| p.N2394K          | Tolerated (Score 0.23) | Possibly damaging | Neutral (NN output 0.5113) |
| p.G3546R          | Affect (Score 0.01) | Probably damaging | Pathogenic (NN output 0.1799) |
| p.E4921K          | Tolerated (Score 0.85) | Benign | Neutral (NN output 0.3130) |
| p.N3894D          | Tolerated (Score 0.05) | Probably damaging | Neutral (NN output 0.0522) |
| p.E4921K          | Tolerated (Score 0.85) | Benign | Neutral (NN output 0.3130) |

*SIFT: SIFT Score ranges from 0 to 1. The amino acid substitution is predicted to be damaging if the score is < 0.05, and tolerated if the score is > 0.05.*

*PolyPhen: “Probably damaging” (it is believed most likely to affect protein function or structure), “Possibly damaging” (it is believed to affect protein function or structure), “Benign” (most likely lacking any phenotypic effect).*

*PMUT: NN output is the original output from the neural network for this mutation and its parameters. If that output is bigger than 0.5 it is predicted as pathogenic, otherwise as neutral.*
stronger expression. For this reason, this change has been classified as UV3.

The majority of mutations were found once or twice. Only the c.2299delG mutation was identified in more than 5 alleles. However, the cohort in our study is biased, because those patients in whom two mutations were detected in previous analyses (study of exon 13, exons 2-21 or microarray analyses) were not included in this work. Actually, the allele frequency of the c.2299delG mutation in the Spanish population is 15%, which is lower, in any case, than in other populations [39].

Figure 2 shows the distribution of all the pathogenic mutations detected in the present study, along the different domains of the USH2A protein. Mutations are located evenly throughout the protein and no “hot spots” were observed. Interestingly, there are two domains in which mutations are not detected: the transmembrane and intracellular domains. None of the studies performed in USH2A have detected mutations in the intracytoplasmic region, involved in the interaction of the USH2A protein with harmonin and whirlin.

There are more than 160 pathogenic variants described in previous studies. Noteworthy, 23 mutations reported in this work are novel. If we compare the mutations detected in this study with those found in other Caucasian populations, only five mutations are common with the studies of Baux et al. (2007) [25] and McGee et al. (2010) [30] and three with the work of Dreyer et al. (2008) [28]. However, we can also find similarities with other populations, like non-Ashkenazi Jews. The splice-site variant c.12062-2A > G was detected in three patients, in homozygous state in one of them. This mutation was initially described by Auslender et al. (2008) [26], as one of the most USH2A prevalent mutations in non-Ashkenazi Jews. Later, it was also detected in the American population [30]. We do not know the origin of our three patients, but it is tempting to speculate that they are descendant of those Sephardic Jews that were expelled from Spain in 1492 [40].

We did not find any mutation in 45 families while in 18 the second mutation remained unidentified. The number of detected pathogenic variants is probably underestimated, because there may be mutations in regions which have not been analyzed (introns, 3’ and 5’ untranslated regions (UTRs), promoter region, distant enhancers...) or large insertions, deletions and rearrangements that cannot be detected with the conventional PCR techniques. Moreover, some of these patients may have mutations in other genes like GPR98, which seems to be responsible for approximately 3-6% of USH2 cases [41,42] or DFNB31, although the studies indicate a minor role of DFNB31 in USH2 [43,44]. Furthermore, USH1 genes may be responsible for phenotypically USH2 patients. Jaijo et al. (2010) [32] found two mutations in CDH23 in two patients diagnosed as USH2 and a high phenotypic heterogeneity due to CDH23 variants has been reported [45,46].

In this report, we have detected at least one mutation in 48.9% (43/88) of total patients. Considering only the patients clearly diagnosed with Usher syndrome type II,
the mutation detection ratio raises to 56.9% (33/58). This detection rate is lower than expected because, as it has been mentioned before, the patient sample included in this study is biased. Thus, if we take into account all our USH2 patients studied so far (including results from previous studies [19, 9, 23, 32], unpublished data and the present work), our database includes 102 typical USH2 patients with at least one mutation detected in the USH2A gene and 32 typical USH2 patients who have been studied for all exons of this gene and no mutation was found (Table 7). Thereby, our mutation detection rate rises considerably to 76.1% (102/134), making our percentage similar to those obtained by Baux et al. (2007) [25] and Dreyer et al. (2008) [28].

Table 7 Comparison between results obtained from the sample included in the present report with the global results for our total series.

|                | PRESENT REPORT SAMPLE | TOTAL SERIES* |
|----------------|-----------------------|--------------|
|                | 0 MUT | 1 MUT | 2 MUT | 1 + 2 MUT | 0 MUT | 1 MUT | 2 MUT | 1 + 2 MUT |
| USH2           | 43.1% (25/58) | 22.4% (13/58) | 34.5% (20/58) | 56.9% (33/58) | 23.9% (32/134) | 16.4% (22/134) | 59.7% (80/134) | 76.1% (102/134) |
| USHA           | 54.5% (6/11) | 18.2% (2/11) | 27.3% (3/11) | 45.5% (5/11) | 33.3% (8/24) | 25% (6/24) | 41.6% (10/24) | 66.7% (16/24) |
| USHNC          | 73.7% (14/19) | 15.8% (3/19) | 10.5% (2/19) | 26.3% (5/18) | 64% (16/25) | 12% (3/25) | 24% (6/25) | 36% (9/25) |
| TOTAL          | 51.1% (45/88) | 20.5% (18/88) | 28.4% (25/88) | 48.9% (43/88) | 30.6% (56/183) | 16.9% (31/183) | 52.5% (96/183) | 69.9% (127/183) |

We consider as a mutation (MUT) only those clearly pathogenic. If we also consider UV3, the total figures in the present report sample are 51.1% (45/88); 17% (15/88) and 48.9% (43/88) for 0 MUT, 1 MUT, 2 MUT and 1 + 2 MUT respectively.

* Percentage of patients with at least one mutation in USH2A: patients with only one mutation + patients with 2 mutations (1MUT + 2MUT).

* TOTAL SERIES represents the global results obtained from this, together with previous studies [19, 9, 23, 32], unpublished data and present work.

Acknowledgements

Authors are grateful to the patients participating in the study and to their family members, and also to the FARPE for their help and co-operation. The exon trapping expression vector pSPL3 was kindly provided by S. Tuffery-Giraud and I. Bottillo. Funding: This work was supported by PI07/0558, PI08/90311 and PI10/01825, from the Spanish Ministry of Science and Innovation and GV/RE/2008/024 from the Conselleria de Sanitat de la Comunitat Valenciana. CIBERER is an initiative of the Institute of Health Carlos III from the Spanish Ministry of Science and Innovation. Gema García-García and María José Aparisi are recipient of a fellowship from the Spanish Ministry of Education (REF: AP2008-02760 and AP2009-3344, respectively). Regina Rodrigo has a Contrato-Investigador SNS Miguel Servet (CP09/118) from Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. Patient consent: obtained; Ethics approval: This study was conducted according to
the tenets of Helsinki declaration and with the approval of the Hospital La Fe ethics committee.

Author details
1 Grupo de Investigación en Enfermedades Neurosensoriales. Instituto de Investigación Sanitaria IIS-La Fe, Valencia, Spain. 2 CIBER de Enfermedades Rasas (CIBERER), Valencia, Spain. 3 Servicio de Genética, Fundación Jiménez Díaz, Madrid, Spain. 4 Servei de Genètica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 5 Instituto de Microscopia Ocular, Barcelona, Spain. 6 Servicio de Oftalmología, Hospital Universitario La Fe, Valencia, Spain.

Authors’ contributions
GG carried out the mutational screening of the USH2A gene in Usher syndrome patients, participated in the minigene constructions and expression and drafted the manuscript. MA carried out the mutational screening of the USH2A gene in controls and participated in the minigene constructions and expression. TJ carried out the Splice-site predictions and drafted the manuscript. RR carried out bioinformatic’s predictions of the pathogenic effect of missense variations. AL participated in the mutational screening of the USH2A gene in Usher syndrome patients. AA and SB participated in patients’ and controls’ genomic DNA extraction. FB participated in clinical anamnestic data collection. RN, MB and CA participated in patient recruitment, pedigree and clinical anamnestic data collection. MD participated in the clinical diagnosis of patients. JM participated in patient recruitment, pedigree and clinical anamnestic data collection and drafted the manuscript. EA coordinated and supervised the study and drafted the manuscript. All authors read and approved the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 4 April 2011 Accepted: 17 October 2011 Published: 17 October 2011

References
1. Keats BJ, Corey DP: The usher syndromes. Am J Med Genet 1999, 89:158-66. Review.
2. Esponòs C, Millán JM, Beneyto M, Nájera C: Epidemiology of Usher syndrome in Valencia and Spain. Community Genet 1998, 1:223-8.
3. Sainah Z, Webster AR, Lucon L, Bítner-Glindzicz M: Update on Usher syndrome. Curr Opin Neurol 2009, 22:19-27.
4. Millán JM, Aller E, Jaijo T, Blanco-Kelly F, Gimenez-Pardo A, Ayuso C: An update on the genetics of usher syndrome. J Ophthalmol 2011, 2011:417217.
5. Rosenberg T, Haim M, Hauch AM, Parving A: Mutations in myosin VIIA (MYO7A) and usherin (USH2A) in Spanish patients with Usher syndrome type I and II, respectively. Hum Mutat 2002, 20:76-77.
6. Pennings RJ, Te Brinke H, Weston MD, Claassen A, Orten DJ, Weerak J, Van Aarem A, Huygen PL, Deutman AF, Cremers CW, Kremer H: Usher syndrome type II.A: high prevalence and phenotypic variation. Am J Hum Genet 1999, 64:1221-1225.
7. Najera C, Beneyto M, Blanca J, Aller E, Fontcuberta A, Millan JM, Ayuso C: Mutations in myosin VIIA (MYO7A) and usherin (USH2A) in Spanish patients with Usher syndrome types I and II. Hum Mutat 2000, 15:186-90.
8. Talmadge CB, Beisel KW, Tamayo M, Morton CC, Swaroop A, Kimberling WJ, Ahmad I, Cheng JJ, Ayuso C, Cremers CW, Davenport S, Muller C, Talmadge CB, Beisel KW, Tamayo M, Morton CC, Swaroop A, Kimberling WJ, Sumegi J: Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science 1998, 280:1753-7.
9. Weston MD, Eudy JD, Fujita S, Yao S, Usami S, Cremers CW, Greenberg J, Ramesar R, Martini A, Muller C, Smith RJ, Sumegi J, Kimberling WJ. Genomic structure and identification of novel mutations in usherin, the gene responsible for Usher syndrome type IIa. Am J Hum Genet 2000, 66:1199-210.
10. van Wijk E, Pennings RJ, te Brinke H, Claassen A, Yntema HG, Hoefslott LH, Cremers FP, Cremers CW, Kremer H: Identification of 51 novel exons of the Usher syndrome type 2A (USH2A) gene that encode multiple conserved functional domains and that are mutated in patients with Usher syndrome type II. Am J Hum Genet 2004, 74:738-44.
11. Adato A, Lefevre G, Delprat B, Michiel V, Michalski N, Chardenoux S, Well D, El-Amraoui A, Petit C: Usherin, the defective protein in Usher syndrome type IIa, is likely to be a component of inter stereocilia ankle links in the inner ear sensory cells. Hum Mol Genet 2005, 14:3921-32.
12. van Wijk E, van der Zwaag B, Peters T, Zimmermann U, te Brinke H, Kersten FF, Marker T, Aller E, Hoefslott LH, Cremers CW, Cremers FP, Wolfrum U, Knipper M, Roempman K, Kremer H: The DFN831 gene product whirin connects to the Usher protein network in the cochlea and retina by direct association with USH2A and VGLUT1. Hum Mol Genet 2006, 15(S):751-65.
13. Liu K, Hope C, Liang CY, Jou M, Xu LR, Cole T, Mueller RF, Bunde S, Nance W, Brown SD: A mutation (2314delG) in the Usher syndrome type II A gene: high prevalence and phenotypic variation. Am J Hum Genet 1999, 64:492-502.
14. Adato A, Weston MD, Berry A, Kimlinger WF, Bonne-Tamir: A Three novel mutations and twelve polymorphisms identified in the USH2A gene in Israeli UHS2 families. Hum Mutat 2000, 15:386-90.
15. Dreyer B, Tranebjærg L, Rosenberg T, Weston MD, Kimlinger WF, Nilsson : Identification of novel USH2A mutations: implications for the structure of USH2A protein. Eur J Hum Genet 2000, 8:500-506.
16. Najera C, Beneyto M, Blanca J, Aller E, Fontcuberta A, Millan JM, Ayuso C: Mutations in myosin VIIA (MYO7A) and usherin (USH2A) in Spanish patients with Usher syndrome types I and II, respectively. Hum Mutat 2002, 20:76-77.
17. Bernal S, Ayuso C, Antiholo G, Gmezene A, Borrego S, Trujillo MJ, Marcos I, Calaf M, Del Rio E, Baigor M: Mutations in USH2A in Spanish patients with autosomal recessive retinitis pigmentosa: high prevalence and phenotypic variation. J Med Genet 2003, 40:68.
18. Pennings RJ, te Brinke H, Weston MD, Claassen A, Otten DJ, Weerak J, Van Aarem A, Huygen PL, Deutman AF, Hoefslott LH, Cremers CW, Cremers CW, Kimberling WJ, Kremer H: Usher syndrome type II.A: full-length Isoform of Usherin Identify New Pathogenic Alleles in Usher Syndrome. J Ophthalmol 2011, 2011:417217.
19. Najera C, Beneyto M, Blanca J, Aller E, Fontcuberta A, Millan JM, Ayuso C: Mutations in myosin VIIA (MYO7A) and usherin (USH2A) in Spanish patients with Usher syndrome types I and II, respectively. Hum Mutat 2000, 20:76-77.
20. Pennings RJ, Te Brinke H, Weston MD, Claassen A, Otten DJ, Weerak J, Van Aarem A, Huygen PL, Deutman AF, Hoefslott LH, Cremers CW, Cremers CW, Kimberling WJ, Kremer H: Usher syndrome type II.A: full-length Isoform of Usherin Identify New Pathogenic Alleles in Usher Syndrome. J Ophthalmol 2011, 2011:417217.
28. Dreyer B, Brox V, Tranebaerg L, Rosenberg T, Sadeghi AM, Möller C, Nilsson O. Spectrum of USH2A mutations in Scandinavian patients with Usher syndrome type II. Hum Mutat 2009, 30(3):347-55.

29. Aronson S, Sjöblom L, Järvemark J, Pettersson F, Ekenstam K, Hultcrantz R, Stål S, Olsson R, Carlsson S, Wahren S. Molecular basis of Usher syndrome. Identifying mutations in 30. McGee TL, Seyedahmadi BJ, Sweeney MO, Dryja TP, Berson EL: mutations in the long isoform of the USH2A gene in patients with Usher Syndrome type II. J Hum Genet 2009, 54(12):732-8.

30. McGee TL, Seyedahmadi BJ, Sweeney MO, Dryja TP, Berson EL: Novel mutations in the long isoform of the USH2A gene in patients with Usher syndrome type II or non-syndromic retinitis pigmentosa. J Med Genet 2010, 47(7):499-506.

31. Le Guéral F, Ménage M, Vaché C, Baux D, Faugère V, Larrieu L, Abadie C, Janecke A, Claustres M, Roux AF, Tuffery-Giraud S. Ex vivo splicing assays of mutations at noncanonical positions of splice sites in Usher genes. Hum Mutat 2010, 31(3):347-55.

32. Jaijo T, Aller E, García-García G, Aparisi MJ, Bernal S, Avila-Fernández A, Baraganà I, Baiget M, Ayuso C, Antrikko G, Diaz-Llops M, Kuhl M, Benezyto M, Nájera C, Millán JM. Microarray-based mutation analysis of 183 Spanish families with Usher syndrome. Invest Ophthalmol Vis Sci 2010, 51(3):1311-7.

33. Jaijo T, Aller E, Aparisi MJ, García-García G, Hernan I, Gamundi MJ, Nájera C, Carballó M, Millán JM. Functional analysis of splicing mutations in MYO7A and USH2A genes. Clin Genet 2011, 79(3):262-8.

34. Mattiti I, De Luca A, Schirinzi A, Guido V, Torrente I, Calveri S, Gervasi C, Larizza L, Pizzuti A, Dallapiccola B. Functional analysis of splicing mutations in exon 7 of NFI gene. BMC Med Genet 2007, 12(8):4.

35. Baux D, Faugère V, Larrieu L, Le Guérad-Méreuze S, Hamroun D, Béroud C, Malcolm S, Claustres M, Roux AF. UMD-USbases: a comprehensive set of databases to record and analyse pathogenic mutations and unclassified variants in seven Usher syndrome causing genes. Hum Mutat 2008, 29(8): E76-E87.

36. Aller E. Molecular bases of Usher syndrome. Identifying mutations in known genes. Functional studies searching for candidate genes. PhD thesis Valencia University, Genetic Department, 2007.

37. de Pontual L, Pelet A, Clement-Ziza M, Trochet D, Antonarakis SE, Attié-Bitach T, Beales PL, Blouin JL, Dastot-Le Moal F, Dollfus H, Goossens M, Katsanis N, Touraine R, Feingold J, Munnich A, Lyonnet S, Amiel J. A common allele in RPGRIP1L is a modifier of retinal degeneration in ciliopathies. Nat Genet 2009, 41(6):739-45.

38. Aller E, Larrieu L, Jaijo T, Baux D, Espinós C, González-Candelas F, Nájera C, Palau F, Claustres M, Roux AF, Millán JM. The USH2A c.2399delG mutation: dating its common origin in a Southern European population. Eur J Hum Genet 2010, 18(7):788-93.

39. Millán JM, Aller E, Jaijo T, Blanco-Kelly F, Corton M, Ayuso C, Kimberling WJ: Mutations in the VLRG1 gene implicate G-protein signaling in the pathogenesis of Usher syndrome type II. Am J Hum Genet 2004, 74:35-66, Erratum in: Am J Hum Genet 2004,74:1080.

40. Ebermann I, Wiesen MH, Zrenner E, López I, Pigeon R, Kohl S, Lowenheim H, Koenekoop RK, Bolz H. GPR98 mutations cause Usher syndrome type 2 in males. J Med Genet 2009, 46(4):277-80.

41. Ebermann I, Scholl HP, Charbel Issa P, Becirovic E, Lamprecht J, Jurkies B, Millán JM, Aller E, Mitter D, Bolz H. A novel gene for Usher syndrome type 2: mutations in the long isoform of whirlin are associated with retinitis pigmentosa and sensorineural hearing loss. Hum Genet 2007, 121:203-11.

42. Aller E, Jaijo T, van Wijk E, Ebermann I, Kersten F, García-García G, Vosseknek K, Aparisi MJ, Hoefloot L, Cremers C, Diaz-Llops M, Pennings R, Bolz HU, Kremer H, Millán JM. Sequence variants of the DFNB31 gene among Usher syndrome patients of diverse origin. Mol Vis 2010, 16(1):495-500.